ATTAIN-1: Investigating Orforglipron for Obesity Management
Om avsnittet
Watch the full interview on YouTube to learn more about the ATTAIN trial, one of the most anticipated studies at the EASD 2025 Annual Meeting.
In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) discuss how the oral small molecule GLP-1 receptor agonist, Orforglipron, could revolutionise diabetes and obesity care. They explore clinical outcomes, the impact on cardiometabolic health, and why oral therapies may be key to making effective treatments accessible worldwide.
Read the full publication in The New England Journal of Medicine for a deeper dive into the data.
Stay tuned for more expert insights and breakthrough conversations from EASD TV. To learn more about our expert speakers:
Diabetes Insights - Breakthroughs and Innovators med EASD - European Association for the Study of Diabetes finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.